Evidence map›Paper›PMID 35218675›Full record

ReviewCancer science2022

Exosomes reveal the dual nature of radiotherapy in tumor immunology.

Xinru Hu, Yuyue Qiu, Xiaoping Zeng, Hongmei Wang

Open access · goldAbstract readReview
In one paragraph

Review in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Xinru HuSchool of Basic Medical Sciences, Nanchang University, Nanchang, China.ORCID https://orcid.org/0000-0002-3891-7434
Yuyue QiuSchool of Basic Medical Sciences, Nanchang University, Nanchang, China.ORCID https://orcid.org/0000-0002-9712-2404
Xiaoping ZengSchool of Basic Medical Sciences, Nanchang University, Nanchang, China.ORCID https://orcid.org/0000-0002-8252-5809
Hongmei WangSchool of Basic Medical Sciences, Nanchang University, Nanchang, China.ORCID https://orcid.org/0000-0002-2703-3406
Nanchang University · CN

Funding

National Natural Science Foundation of China 81860540National Natural Science Foundation of China 82060526
6 · The paper itself

Abstract

Radioresistance is the potential cause of cancer metastasis and recurrence. Radiation-induced changes in exosomes can partially explain the undesirable prognosis of radiotherapy (RT). Exosomes, newly discovered ways of cell communication, carry the characteristics of their origin, resulting in their diversity. Various exosomes in the tumor microenvironment exert different function in immune response. In this review, the dual effect of RT on the immune system was described, and the effect of radiotherapy on tumors via exosomes was explored. The molecules in exosomes after RT were described to play immunosuppressive and immunocompetent roles: immune-related receptors and cell signaling molecules involved in both adaptive and innate immune system were present. CD69, TIGIT, TIM-3, LAG-3 and the tumor necrosis factor (TNF) family that signal to T cells were shown to be regulated by exosomes after irradiation. The change in innate immunity-derived like receptors, Leukocyte Immunoglobin-Like Receptors (LILR) was described, as well as B7-H3, V-domain containing Ig suppressor of T cell activation (VISTA), and CD155 on tumor cells. These changed molecules inhibit and activate the immune system through different mechanisms. By analyzing the relationship between exosome-derived molecules and immunity, this review shows that radiotherapy can induce immunosuppression and immune clearance through exosomes, thereby treating tumors and improving patient prognosis.

Indexed as

ExosomesNeoplasmsCell CommunicationHumansPrognosisTumor Microenvironmentcancerexosomeimmunomodulationradiotherapy

Identifiers

PMID35218675
PMCPMC8990792
OpenAlexW4214632897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.